AU - Elnajjar, Mostafa AU - Dawood, Alaaeldin AU - Soliman, Mahmoud AU - Khalil, Gihane AU - Amin Elzorkany, Khaled AU - Aglan, Mohamed TI - Serum chemerin and its association with coronary heart disease in diabetic and nondiabetic patients PT - ORIG DP - 2018 Apr 1 TA - Menoufia Medical Journal PG - 474-480 VI - 31 IP - 2 4099- http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2018;volume=31;issue=2;spage=474;epage=480;aulast=Elnajjar;type=0 4100- http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2018;volume=31;issue=2;spage=474;epage=480;aulast=Elnajjar AB - Objective Chemerin is a novel adipokinine that is associated with inflammation and adipogenesis. Our aim was to study the relationship between serum chemerin and coronary artery disease (CAD) in angiographically documented participants and participants without CAD among patients with diabetes mellitus and those without diabetes mellitus. Background Chemerin is one of the adipokines that is linked to fat metabolism and thought to be linked to atherosclerosis and CAD. Patient and methods This cross-sectional study was conducted on 80 patients recruited from among patients presenting to the catheter laboratory of Sharq Al-Madina Hospital in Alexandria. Participants were divided into the following groups: group 1 included 20 diabetic patients with CAD; group 2 included 20 diabetic patients without CAD; group 3 included 20 nondiabetic patients with CAD; and group 4 included 20 participants as controls. Patients of groups 1 and 3 had angiographically documented CAD. Serum chemerin, glycemic control parameters (fasting blood sugar, glycated hemoglobin, fasting insulin, and homeostasis model assessment for insulin resistance), lipid profile, and urinary albumin–creatinine ratio were assessed. Results The results of the present study showed that there was a statistically significant increase in mean serum chemerin level in group 1 compared with groups 2 and 4 (P = 0.007and 0.001, respectively), as well as compared with group 3, but this increase was not statistically significant. There was also a statistically significant increase in serum chemerin in group 3 compared with groups 2 and 4 (P = 0.001 and 0.003, respectively). However, there was no statistically significant difference between the two CAD groups (groups 1 and 3) with regard to the Gensini score. There was no statistically significant correlation among the other studied parameters. Conclusion Serum chemerin level was increased in CAD patients, irrespective of whether they were diabetic or nondiabetic, but did not increase as the severity of CAD increased when assessed by the Gensini score.